Tumour defence mapping
Tumour microenvironment (TME) comprises the cells and signals surrounding a tumour that can suppress or enable an immune response. ONVAC™ performs deep TME and clonality mapping that evaluates immunosuppressive risk.
Decoding Cancer. Designing Smarter Vaccines.
We decode tumour biology to find the best targets, profile the tumour microenvironment to predict who will respond, and turn that intelligence into manufacturing-ready mRNA cancer vaccines at scale, reducing time and risk at every step from data to clinic.
The Problem
Cancer vaccines are one of oncology's most promising treatments, but the field isn't built to deliver them at scale.
Cancer kills nearly 10 million people worldwide every year, largely in cancers where options are limited and survival has barely improved in decades.
Oncology is also one of the highest-attrition areas in drug development: only around 5% of programmes entering Phase I reach approval, often due to mis-selected targets, poorly understood tumour microenvironments, and weak patient stratification.
10M
deaths from cancer worldwide each year
~5%
of oncology programmes entering Phase I reach approval
The Solution
ONVAC™: AI infrastructure that converts tumour data into manufacturing-ready cancer vaccines.
Oncocine has built ONVAC™ to address the core failure points in cancer vaccine programmes: mis-selected antigens, uncharacterised tumour microenvironments, poor patient stratification, and weak manufacturing readiness.
Manufacturing-ready designs
An AI asset engine that converts validated biology into codon-optimised mRNA vaccine designs, eliminating manual steps, reducing COGS and time to clinic.
Partner with us to build the next generation of cancer vaccines, faster, safer, and at scale.
Schedule a conversation with our team.
Get in Touch